Study finds gaps in recommended cardiac amyloidosis testing

Many patients evaluated for two common forms of cardiac amyloidosis never received the testing recommended to confirm or rule out the diseases, a large analysis of U.S. electronic health records found. This gap can delay treatment for conditions in which timely care is crucial, according to the study authors.

The retrospective study, published in eJHaem, drew on de-identified electronic health record (EHR) and integrated claims-clinical data covering January 2017 through June 2023. Investigators led by Muhamed Baljevic, M.D., of Vanderbilt University Medical Center, examined the diagnostic workups recorded in the 24 months before a first diagnosis of light chain (AL) amyloidosis, wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM), or both.